Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 21Lymphoma, Large B-Cell, Diffuse 9Recurrence 8Leukemia, Myeloid, Acute 4Sarcoma 3Endometrial Neoplasms 3Primary Myelofibrosis 2Neurofibrosarcoma 2Neoplasms 2Myeloproliferative Disorders 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell 2Glioblastoma 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Vascular Neoplasms 1Uterine Neoplasms 1Uterine Diseases 1Triple Negative Breast Neoplasms 1Solitary Fibrous Tumors 1Smooth Muscle Tumor 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Salivary Gland Neoplasms 1Rhabdoid Tumor 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Nerve Sheath Neoplasms 1

Interventions

Rituximab 16zanubrutinib 12ibrutinib 9venetoclax 8Cyclophosphamide 8pirtobrutinib 5fludarabine phosphate 5Whole-Body Irradiation 5Sirolimus 5Mycophenolic Acid 5Bendamustine Hydrochloride 5acalabrutinib 4Peripheral Blood Stem Cell Transplantation 4Dexamethasone 4ixazomib 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Lenalidomide 3Cyclosporine 3Bortezomib 3Biopsy 3fludarabine 2carfilzomib 2Tacrolimus 2Prednisone 2Melphalan 2Etoposide 2Cyclosporins 2Calcium Dobesilate 2CT-P10 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Waldenstrom Macroglobulinemia × selinexor × 1 year × Clear all
NCT03147885 2025-09-29

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

Barbara Ann Karmanos Cancer Institute

Phase 1/2 Active not recruiting
43 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡